Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid Induced Constipation Clear all
Completed Phase 2 Interventional

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

NCT01100151
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
RDC-1036 (ALKS 37), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Sheffield, Alabama • Anaheim, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

NCT00101998
View directory record Official record
Conditions
Constipation, Bowel Dysfunction
Interventions
alvimopan, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00241722
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 21, 2026, 10:40 PM EDT
Terminated Phase 2 Interventional Results available

Naloxegol in Cancer Opioid-Induced Constipation

NCT02745353
View directory record Official record
Conditions
Constipation
Interventions
naloxegol
Drug
Lead sponsor
Joseph Ma
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 21, 2026, 10:40 PM EDT
Recruiting No phase listed Observational

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

NCT03720613
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Lubiprostone, Naloxegol
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
34,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 21, 2026, 10:40 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00414024
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00256932
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
137
States / cities
Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 21, 2026, 10:40 PM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

NCT00365820
View directory record Official record
Conditions
Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Timeline
2006 – 2007
U.S. locations
59
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

NCT01418092
View directory record Official record
Conditions
OIC
Interventions
ALKS 37, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Anaheim, California • Orange, California • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Naldemedine

NCT01965652
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Not applicable Interventional Results available

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

NCT00662363
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone, Senna
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 4 Interventional Results available

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

NCT03523520
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

NCT01367574
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
SC MNTX
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 10:40 PM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

NCT01459926
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Foley, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

NCT01382797
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
ALKS 37, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • National City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Jul 21, 2026, 10:40 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00399659
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2006 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Jul 21, 2026, 10:40 PM EDT
Not listed No phase listed Observational

Naloxegol US PMR CV Safety.

NCT02813356
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
naloxegol, non-PAMORA
Drug
Lead sponsor
Valinor Pharma LLC
Industry
Eligibility
Not listed
Enrollment
8,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Wilmington, Delaware • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 21, 2026, 10:40 PM EDT